625437-38-9

Basic information

• Product Name: N-(2,3-diMethylbenzyl)cyclopropanaMine
• Synonyms: N-(2,3-diMethylbenzyl)cyclopropanaMine;N-(2,3-diMethylbenzyl)cyclopropanaMine hydrochloride;BenzeneMethanaMine, N-cyclopropyl-2,3-diMethyl-
• CAS NO: 625437-38-9
• Molecular Formula: C₁₂H₁₇N
• Molecular Weight: 175
• Mol File: 625437-38-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2,3-diMethylbenzyl)cyclopropanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,3-diMethylbenzyl)cyclopropanaMine(625437-38-9)
• EPA Substance Registry System: N-(2,3-diMethylbenzyl)cyclopropanaMine(625437-38-9)

Safety Data

• Hazardous Substances Data: 625437-38-9(Hazardous Substances Data)

Usage

Description

N-(2,3-diMethylbenzyl)cyclopropanaMine is a versatile organic compound belonging to the cyclopropanes class. It features a cyclopropane ring with a benzyl group and two methyl groups attached to its carbon atoms, making it a valuable building block in pharmaceutical synthesis and a reagent for creating complex molecules in organic synthesis.

Uses

Used in Pharmaceutical Industry:
N-(2,3-diMethylbenzyl)cyclopropanaMine is used as a building block for the synthesis of various pharmaceutical compounds, leveraging its unique structural properties to contribute to the development of new medications.
Used in Organic Synthesis:
In the field of organic synthesis, N-(2,3-diMethylbenzyl)cyclopropanaMine serves as a reagent to create complex molecules, enabling chemists to explore a wide range of chemical reactions and processes due to its versatile structure.

Upstream product

• 5779-93-1 2,3-dimethylbenzaldehyde 
• 765-30-0 Cyclopropylamine 
• 940774-65-2 N-cyclopropyl-2,3-dimethylbenzamide 
• 603-79-2 2,3-dimethylbenzoic acid 

Downstream Products

• 916337-21-8 C₃₄H₃₉N₃O₄ 
• 1443056-92-5 N-cyclopropyl-4-(3 ,4-difluorobenzamido)-N-(2,3-dimethylbenzyl)piperidine-3-carboxamide hydrochloride 
• 1056555-00-0 (2E)-2-cyano-N-cyclopropyl-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-N-(2,3-dimethylbenzyl)acrylamide 
• 1041439-47-7 3-benzyl-N-cyclopropyl-7-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-N-(2,3-dimethylbenzyl)-9-[(1R)-1-phenylethyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide 
• 949152-12-9 (rac)-3-[cyclopropyl(2,3-dimethylbenzyl)carbamoyl]-4-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 909702-86-9 N-(2,3-dimethylbenzyl)cyclopropanamine hydrochloride 
• 930798-43-9 (3R,4S)-1-benzyl-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}pyrrolidine-3-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide 
• 948558-69-8 2-cyano-N-cyclopropyl-N-(2,3-dimethyl-benzyl)-acetamide 

Relevant articles and documents

COMPOUNDS AS INHIBITORS OF RENIN

The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to

Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors

Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent attached at the position 3 did not modify the binding affinity but allowed the modulation of the ADME properties. Our efforts led to the discovery of compound (+)-26g that inhibits renin with an IC 50 of 0.20 nM in buffer and 19 nM in plasma. The pharmacokinetics properties of this and other similar compounds are discussed. Compound (+)-26g is well absorbed in rats and efficacious at 10 mg/kg in vivo.

RENIN INHIBITORS

The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.